Opinion|Videos|February 10, 2025
Progression on BTK Inhibitors: Treatment Options and Considerations
Panelists comment on the role of combination venetoclax-ibrutinib in this setting and available supporting data.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly comment on the role of combination venetoclax-ibrutinib in this setting and available supporting data (high level).
- What is the potential role for venetoclax in combination with 2nd generation BTKis in this setting? (
Ahn IE, et al. ASH 2024. Abs 1874 ) - Briefly review recent ESMO guideline updates for managing patients with R/R CLL who experience disease progression on a BTKi. (
ESMO CLL Guideline Update 2024 ) - How does your treatment approach differ for patients who progress on first-line BTK inhibitor therapy versus those who are intolerant to it?
- When would you opt for an alternative BTKi vs changing to a venetoclax-based regimen?
Advertisement
Related to this article
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
The NMPA has approved pirtobrutinib in treatment-naive and previously treated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
2
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
3
VIR-5500 Receives FDA Fast Track Designation in mCRPC
4
MAVERICK, B7-H3–Directed ADCs, and ADAURA Data Headline Key Lung Cancer Findings From WCLC 2026
5